Clinical difference of interstital lung disease patients positive for anti-amnioacyl-tRNA (ARS) synthetase antibodies between dermatomyositis/polymyositis (PM/DM) group and non-myosits group

M. Momose (Kurashiki, Japan), M. Arita (Kurashiki, Japan), T. Ishida (Kurashiki, Japan)

Source: International Congress 2022 – Clinical course and management of interstitial lung diseases

Session: Clinical course and management of interstitial lung diseases
Session type: Thematic Poster
Number: 1962

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Momose (Kurashiki, Japan), M. Arita (Kurashiki, Japan), T. Ishida (Kurashiki, Japan). Clinical difference of interstital lung disease patients positive for anti-amnioacyl-tRNA (ARS) synthetase antibodies between dermatomyositis/polymyositis (PM/DM) group and non-myosits group. 1962

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.